Key Documents

View All Documentation

SML0881

Rivastigmine tartrate

Name: Rivastigmine tartrate
Brand: SIGMA

≥98% (HPLC), cholinesterase inhibitor, powder

Synonym(s):

ENA-713, Ethylmethyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester, N-Ethyl-N-methyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester tartrate, S-Rivastigmine tartrate

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₄H₂₂N₂O₂· C₄H₆O₆

CAS Number:

129101-54-8

Molecular Weight:

400.42

UNSPSC Code:

12352200

NACRES:

NA.77

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Storage condition:

desiccated

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

Rivastigmine tartrate, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H₂O: 15 mg/mL, clear

storage temp.

2-8°C

SMILES string

N([C@@H](C)c1cc(ccc1)OC(=O)N(CC)C)(C)C.O[C@@H]([C@H](O)C(=O)O)C(=O)O

InChI

1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/m00/s1

InChI key

GWHQHAUAXRMMOT-RWALOXMOSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Bioactive Small Molecule Inhibitors

Bioactive Small Molecules

General description

Rivastigmine tartrate is a cholinesterase inhibitor. It is also called as exelon.

Application

Rivastigmine tartrate has been used in cholinesterase inhibition assay.

Biochem/physiol Actions

Rivastigmine tartrate is used to treat Alzheimer′s disease. It helps to improve thinking ability. It helps to increase cholinergic function by inhibiting acetylcholinesterase.

Rivastigmine is an orally available, brain penetrant, reversible cholinesterase inhibitor that enhances cognitive function in patients with Alzheimer′s and Parkinson′s diseases. Rivastigmine inhibits both butyrylcholinesterase and acetylcholinesterase.

Rivastigmine is an orally available, brain penetrant, reversible cholinesterase inhibitor.

Features and Benefits

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound is featured on the Acetylcholine Synthesis and Metabolism page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

pictograms

GHS06,GHS09

signalword

Danger

hcodes

H300,H411

pcodes

P264 - P270 - P273 - P301 + P310 - P391 - P405

Hazard Classifications

Acute Tox. 2 Oral - Aquatic Chronic 2

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

0000444328

0000425078

0000403323

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Desk Reference of Clinical Pharmacology, Second Edition, 824-824 (2007)

2, 4-Disubstituted quinazolines as amyloid-β aggregation inhibitors with dual cholinesterase inhibition and antioxidant properties: Development and structure-activity relationship (SAR) studies.

Mohamed T and Rao PPN

European Journal of Medicinal Chemistry, 126, 823-843 (2017)

The Complete Pill Guide, 1151-1151 (2003)

The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen.

Emily J Henderson et al.

BMC neurology, 13, 188-188 (2013-12-05)

Gait impairment is common in people with Parkinson's disease. There is a lack of effective interventions to target this debilitating complication and therefore a need to identify new therapeutic options. An underlying cholinergic deficit contributes to both the gait and

A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.

Carina Wattmo et al.

Clinical interventions in aging, 8, 329-339 (2013-05-18)

To investigate the long-term effects of cholinesterase inhibitor (ChEI) therapy and the influence of sociodemographic and clinical factors on the use of community-based home help services (HHS) by patients with Alzheimer's disease (AD). This 3-year, prospective, multicenter study included 880

View All Related Papers

Articles

Acetylcholine Synthesis and Metabolism

Acetylcholine is synthesized from acetyl coenzyme A and choline by the enzyme choline acetyltransferase. In addition to its synthesis in the liver, choline employed in acetylcholine production is derived from dietary sources.

DISCOVER Bioactive Small Molecules for Neuroscience

乙酰胆碱合成及代谢

乙酰胆碱由胆碱乙酰转移酶从乙酰辅酶A和胆碱合成而来。用于生成乙酰胆碱的胆碱除了在肝脏中合成外，还来源于膳食。

Global Trade Item Number

SKU	GTIN
SML0881-50MG	04061835253456

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service